mRNA |
selumetinib:piperlongumine (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.089 |
0.01 |
mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.089 |
0.01 |
mRNA |
avrainvillamide |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.01 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.01 |
mRNA |
Doxorubicin |
GDSC1000 |
pan-cancer |
AAC |
-0.09 |
0.01 |
mRNA |
NVP-BEZ235 |
GDSC1000 |
pan-cancer |
AAC |
-0.085 |
0.01 |
mRNA |
navitoclax:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.09 |
0.01 |
mRNA |
Obatoclax Mesylate |
CTRPv2 |
pan-cancer |
AAC |
0.083 |
0.01 |
mRNA |
N9-isopropylolomoucine |
CTRPv2 |
pan-cancer |
AAC |
0.089 |
0.01 |
mRNA |
RAF265 |
CCLE |
pan-cancer |
AAC |
-0.12 |
0.01 |